Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer
Saved in:
| Published in: | Cancer Medicine |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869663126076522497 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Cancer Medicine |
| description | |
| discipline_display | Oncology |
| discipline_facet | Oncology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:98766 |
| institution | FRELIP |
| journal_source_facet | Cancer Medicine |
| last_indexed | 2026-07-03T03:35:02.293Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer Oncology General Oncology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Oncology General Oncology |
| subject_facet | Oncology General Oncology |
| title | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer |
| title_alt | La elevación de la proporción de eosinófilos después de pembrolizumab aumenta el riesgo de eventos adversos relacionados con el sistema inmunitario en pacientes con cáncer de vejiga L'élévation de la proportion d'éosinophiles après pembrolizumab augmente le risque d'événements indésirables liés à l'immunité chez les patients atteints de cancer de la vessie Elevação da Proporção de Eosinófilos Após Pembrolizumabe Aumenta o Risco de Eventos Adversos Relacionados ao Sistema Imune em Pacientes com Câncer de Bexiga |
| title_auth | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer |
| title_es_txt | La elevación de la proporción de eosinófilos después de pembrolizumab aumenta el riesgo de eventos adversos relacionados con el sistema inmunitario en pacientes con cáncer de vejiga |
| title_fr_txt | L'élévation de la proportion d'éosinophiles après pembrolizumab augmente le risque d'événements indésirables liés à l'immunité chez les patients atteints de cancer de la vessie |
| title_full | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer |
| title_fullStr | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer |
| title_full_unstemmed | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer |
| title_pt_txt | Elevação da Proporção de Eosinófilos Após Pembrolizumabe Aumenta o Risco de Eventos Adversos Relacionados ao Sistema Imune em Pacientes com Câncer de Bexiga |
| title_short | Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer |
| title_sort | elevation of eosinophil proportion after pembrolizumab increases the risk of immune‐related adverse events in patients with bladder cancer |
| topic | Oncology General Oncology |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cam4.72072?af=R |